Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Sinsin Pharmaceutical Co., Ltd. is a prominent entity in the healthcare sector, primarily engaged in the production and distribution of pharmaceutical products. Focused on delivering high-quality medication, the company dedicates itself to researching and developing innovative solutions that address various health conditions. Its product lineup includes prescription drugs, over-the-counter remedies, and therapeutic pharmaceuticals designed to meet diverse consumer health needs. Sinsin Pharmaceutical operates within industries such as healthcare, biotechnology, and medical supplies, impacting both domestic and international markets through its widespread distribution channels. As a vital component of the pharmaceutical industry, the company plays a significant role in enhancing global health standards by ensuring accessibility to essential medications and fostering advancements in medical treatment. Headquartered in South Korea, Sinsin Pharmaceutical continues to contribute to the healthcare landscape with a commitment to quality assurance and regulatory compliance, positioning itself as a trusted provider within the medical community.
₩4,375.00
+₩120.00 (+2.82%)
Live · 11:11 AM
Operating margin is thin at 9.48%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 6.9%, steady but not accelerating.
Net debt of ₩39.82B represents 5.7x FCF, leverage limits flexibility.
6.0x earnings, 6.6x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
₩118.65B
▲ +6.9% YoY
Net Income (TTM)
₩11.15B
▲ +92.9% YoY
Op. Margin
10.70%
▲ +3.0pp YoY
ROIC
8.90%
▲ +3.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
₩10.11B
▲ +57.4% YoY
Op. Cash Flow (TTM)
₩13.05B
▲ +44.2% YoY
Net Debt
₩39.82B
Cash & Equiv.
₩3.88B
3Y CAGR: +7.4%
3Y CAGR: +16.4%
Continue Research
At a P/E of 6.0 and a price-to-free-cash-flow of 6.6, Sinsin Pharmaceutical Co. (002800.XKRX) trades below a two-stage DCF intrinsic value of about KRW 31,055.10 per share, so at KRW 4,375.00 the stock looks undervalued (609.8% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Sinsin Pharmaceutical Co. scores 78/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 1.4%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about KRW 31,055.10 per share for 002800.XKRX, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around KRW 23,291.33. At today's KRW 4,375.00, that puts the stock about 609.8% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Sinsin Pharmaceutical Co. scores 78 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a 10.7% operating margin and a 8.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Sinsin Pharmaceutical Co. pays a regular dividend of about KRW 60.07 per share per year (typically in quarterly installments), a yield of roughly 1.4% at the current price. That is a payout ratio of about 8.2% of earnings, so the dividend is amply covered by earnings. Sinsin Pharmaceutical Co. has grown the dividend at roughly 9.5% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For 002800.XKRX's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. 002800.XKRX currently trades below its estimated intrinsic value and scores 78/100 on quality (solid). It also yields about 1.4%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.